Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04904926 · ClinicalTrials.gov registry record
Investigating Loss of Neuromuscular Junction Transmission Fidelity in Older Adults
A clinical trial, sponsored by NMD Pharma A/S.
- Completed
- Registry status
- 19
- Enrollment target
NCT04904926 is a clinical trial that has completed, run by NMD Pharma A/S. The registered enrollment target is 19 participants.
The verdict
NCT04904926 has completed, sponsored by NMD Pharma A/S.
- COMPLETED
- Registry status
- 19 participants
- Enrollment target
Study Summary
Sarcopenia is a condition characterised by age-related loss of muscle mass and function. Factors affecting the strength of muscle contraction independent of mass, such as neuromuscular junction (NMJ) transmission, are increasingly suspected as important contributors to the development of age-related physical disability. The group of investigators leading the current study, have recently demonstrated NMJ transmission deficits in aged mice, but whether this translates in older human individuals is not known The primary aim is to assess whether clinically meaningfull muscle weakness is associated with NMJ transmission deficits in older human individuals with clinically meaningfull muscle weakness. The secondary aim is to assess whether NMJ transmission deficits correlate with different measures of functional capacity to inform future trials of the most appropriate choice of tests.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2021-03-16 |
| Est. Completion | 2021-09-22 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04904926
The ClinicalTrials.gov registry entry for NCT04904926 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NMD Pharma A/S, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04904926 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04904926 about?
NCT04904926 is a clinical study titled "Investigating Loss of Neuromuscular Junction Transmission Fidelity in Older Adults". Sarcopenia is a condition characterised by age-related loss of muscle mass and function. Factors affecting the strength of muscle contraction independent of mass, such as neuromuscular junction (NMJ) transmission, are increasingly suspected as important contributors to the development of age-related...
What is the current status of trial NCT04904926?
This trial is currently completed. The enrollment target is 19 participants. The study started on 2021-03-16. Estimated completion is 2021-09-22.
Who is sponsoring clinical trial NCT04904926?
This trial is sponsored by NMD Pharma A/S, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.